Compare Aspen Aerogels Inc (ASPN) vs GSK plc (GSK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Aspen Aerogels Inc vs GSK plc — how do they compare? Aspen Aerogels Inc trades at $5.25 (market cap $427.65M), while GSK plc trades at $52.5 (market cap $103.72B). The key difference: GSK plc is far larger — about 242.5× Aspen Aerogels Inc's market cap, and GSK plc pays a 3.4% dividend while Aspen Aerogels Inc pays none. Which is the better fit depends on your goals.
| ASPN | GSK | |
|---|---|---|
Market Cap | $427.65M | $103.72B |
Sector | Technology | Health |
52-Week High | $8.82 | $61.18 |
52-Week Low | $2.57 | $36.20 |
Enterprise Value | $382.60M | $124.33B |
Dividend Yield | — | 3.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ASPN trades at $5.16, down 1.53% on the day, with a bearish technical signal despite oversold RSI readings. The company reported a Q1 2026 loss of $0.28 per share, missing estimates, but revenue beat expectations. Recent news includes a 2025 Supplier of the Year award from General Motors and the staged restart of its East Providence facility. Financials show significant net losses but improving cash flow trends into 2026.
Outlook remains challenging with persistent losses and negative margins, though analyst consensus is strongly bullish (83% buy ratings). Key risks include execution on facility restarts and EV demand volatility. The stock offers high-risk growth potential if operational improvements and electrification trends accelerate profitability.
GSK trades at $52.78, up 0.59% today, with a bullish technical signal from moving averages and a neutral RSI. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS expected at $1.27. Revenue grew to $32.67B in 2025, with a net income margin of 17.78%. Recent news includes FDA approval for Utebzi and a $10.6B acquisition of Nuvalent to bolster its oncology pipeline.
GSK presents a balanced outlook with solid profitability and strategic growth in oncology, but faces risks from clinical trial setbacks and competitive pressures. Analyst sentiment is mixed, with 31% buy ratings, suggesting cautious optimism amid pipeline execution uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Aspen Aerogels Inc
Aspen Aerogels is an aerogel technology company that designs high-performance insulation. Its products are used in energy infrastructure and electric vehicles to provide thermal management and fire protection.
Read more on ASPN →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
